Ligilactobacillus salivarius UCC118
Ligilactobacillus salivarius UCC118 is a well-studied gastrointestinal strain notable for its production of Abp118, a broad-spectrum bacteriocin (a ribosomally synthesized antimicrobial peptide), which has been studied in the context of competitive exclusion of pathogens in the gut. Animal studies using DSS-induced colitis models have examined this strain in the context of intestinal inflammation and microbiota composition. An observational study in healthy human athletes examined UCC118 supplementation in relation to exercise-induced intestinal permeability changes (commonly called 'leaky gut'), though this was a small, non-randomized investigation. In vitro research has documented how the strain interacts with epithelial cells and macrophages. These are research topics, not findings; the papers do not establish that this strain treats or prevents any condition.
Where it's been studied Tags come from a conservative keyword scan of each paper's title, abstract, and summary. A tag is research coverage, not measured effect. How we classify this →
Share of this strain's 44 body-system-tagged papers that concern each system. Research coverage, not measured effect.
Symptoms in the research A tag means the paper's text names the symptom or condition — research coverage, not evidence of benefit. How we classify this →
Share of this strain's 12 symptom-tagged papers that mention each symptom or condition. Research coverage, not evidence of benefit.
Research Study-type filters use AI-classified labels, audited but not guaranteed — check the paper itself before leaning on one. How we classify this →
60 papers reference this strain in the probiotic database.
Discussion
Be the first to comment.
Sign in to join the discussion.
Citations
Selected papers that name this strain.
-
[1]
PMID 35889102 →Lactobacillus salivarius UCC118™ Dampens Inflammation and Promotes Microbiota Recovery to Provide Therapeutic Benefit in a DSS-Induced Colitis Model· Microorganisms · 2022
-
[2]
PMID 31758610 →UCC118 supplementation reduces exercise‐induced gastrointestinal permeability and remodels the gut microbiome in healthy humans· Physiological Reports · 2019
-
[3]
Source →A one year, randomised, double blind, placebo controlled trial of probiotics. Bifidobacterium infantis 35624 or Lactobacillus salivarious UCC118, as food supplements for maintenance of remission in Ulcerative colitis.· · 2012
-
[4]
Source →A Randomised Controlled Trial of a Probiotic Lactobacillus Strain in Healthy Adults: Assessment of its Delivery, Transit and Influence on Microbial Flora and Enteric Immunity· Microbial Ecology in Health and Disease · 2002
-
[5]
Source →A Randomised Controlled Trial of a Probiotic Lactobacillus Strain in Healthy Adults: Assessment of its Delivery, Transit and Influence on Microbial Flora and Enteric Immunity· Microbial Ecology in Health and Disease · 2002